Cargando…

Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: analyses from the Phase III LUME-Lung 1 study

BACKGROUND: Nintedanib in combination with docetaxel is approved in the European Union and other countries for the treatment of patients with advanced non-small-cell lung cancer (NSCLC) of adenocarcinoma histology after first-line chemotherapy, based on the overall survival findings of Phase III LUM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reck, Martin, Mellemgaard, Anders, Novello, Silvia, Postmus, Pieter E, Gaschler-Markefski, Birgit, Kaiser, Rolf, Buchner, Hannes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6084077/ https://www.ncbi.nlm.nih.gov/pubmed/30122949 http://dx.doi.org/10.2147/OTT.S170722

Ejemplares similares

Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer
por: Gaschler-Markefski, Birgit, et al.
Publicado: (2017)

Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib
por: Reck, Martin, et al.
Publicado: (2015)

Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study
por: Van Cutsem, E, et al.
Publicado: (2018)

Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO
por: Grohé, Christian, et al.
Publicado: (2022)

Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLC
por: Westeel, Virginie, et al.
Publicado: (2023)

Successful treatment with docetaxel plus nintedanib in a patient with lung adenocarcinoma and pulmonary fibrosis: A case report and literature review
por: Zlatanova, Tanya, et al.
Publicado: (2022)

Trachoma and its determinants in Mojo and Lume districts of Ethiopia
por: Yalew, Kassahun Negash, et al.
Publicado: (2012)

Nintedanib plus Docetaxel after Immune Checkpoint Inhibitor Failure in Patients with Advanced Non-Small-Cell Lung Cancer: A Case Series
por: Hochmair, Maximilian Johannes, et al.
Publicado: (2022)

Efficacy of Combination Docetaxel and Nintedanib in Advanced Non-Small Cell Lung Cancer in Thailand: A Multicenter Study
por: Korphaisarn, Krittiya, et al.
Publicado: (2021)

Sickness absenteeism and associated factors among horticulture employees in lume district, southeast Ethiopia
por: Tadesse, Sebsibe, et al.
Publicado: (2015)

Activation of Human Auditory Cortex in Retrieval Experiments: An fMRI Study
por: Gaschler-Markefski, Birgit, et al.
Publicado: (1998)

Real-World Evidence: Multicenter Efficacy and Toxicity Analysis of Nintedanib With Docetaxel as Second-Line Treatment in Mexican Patients With Advanced Lung Adenocarcinoma
por: Rodríguez-Cid, Jeronimo Rafael, et al.
Publicado: (2020)

Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis
por: Ljubicic, Lidija, et al.
Publicado: (2023)

Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review
por: Garon, Edward B., et al.
Publicado: (2023)

Talaromycosis in a Patient on Nintedanib for Interstitial Lung Disease
por: Madgula, Anantha Sriharsha, et al.
Publicado: (2020)

Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
por: Lamb, Yvette N.
Publicado: (2021)

Vardenafil Activity in Lung Fibrosis and In Vitro Synergy with Nintedanib
por: Bourne, Michael H., et al.
Publicado: (2021)

Nintedanib in children and adolescents with fibrosing interstitial lung diseases
por: Deterding, Robin, et al.
Publicado: (2023)

An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy
por: Yamamoto, Noboru, et al.
Publicado: (2018)

Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer
por: Hamai, Kosuke, et al.
Publicado: (2023)

Safety of nintedanib before lung transplant: an Italian case series
por: Balestro, Elisabetta, et al.
Publicado: (2018)

Therapeutic effect of nintedanib on acute exacerbation of interstitial lung diseases
por: Ito, Yoko, et al.
Publicado: (2019)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
por: Wollin, Lutz, et al.
Publicado: (2019)

Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
por: Cottin, Vincent, et al.
Publicado: (2021)

Evaluation of Pirfenidone and Nintedanib in a Human Lung Model of Fibrogenesis
por: Roach, KM, et al.
Publicado: (2021)

Effects of nintedanib by inclusion criteria for progression of interstitial lung disease
por: Maher, Toby M., et al.
Publicado: (2022)

Correction to: Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
por: Lamb, Yvette N.
Publicado: (2021)

Nintedanib treatment for bleomycin-induced lung injury - First report
por: Rnjak, Dina, et al.
Publicado: (2023)

A randomized phase III study of docetaxel alone versus docetaxel plus S‐1 in patients with previously treated non‐small cell lung cancer: JMTO LC09‐01
por: Atagi, Shinji, et al.
Publicado: (2023)

Radiation-Induced Lung Injury With Lung Cancer Treated With the Combination Therapy of Nintedanib and Dexamethasone
por: Itano, Junko, et al.
Publicado: (2023)

Randomized phase II trial of S‐1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non‐small cell lung cancer
por: Shimokawa, Tsuneo, et al.
Publicado: (2020)

Docetaxel versus docetaxel plus cisplatin for non-small-cell lung cancer: a meta-analysis of randomized clinical trials
por: Li, Ang, et al.
Publicado: (2017)

Clinical development of nintedanib for advanced non-small-cell lung cancer
por: Takeda, Masayuki, et al.
Publicado: (2015)

Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis
por: Lancaster, Lisa, et al.
Publicado: (2020)

The Effect of Nintedanib in Post-COVID-19 Lung Fibrosis: An Observational Study
por: Saiphoklang, Narongkorn, et al.
Publicado: (2022)

Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel
por: Gandara, David, et al.
Publicado: (2021)

nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)
por: Morgensztern, Daniel, et al.
Publicado: (2021)

Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib
por: Woodcock, Hannah V, et al.
Publicado: (2013)

Nintedanib prevented fibrosis progression and lung cancer growth in idiopathic pulmonary fibrosis
por: Fukunaga, Kentaro, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_eq727g44ggk5h68t407g6dmtom